Cancer Clinical Investigation

Search results

• Immunotherapy before surgery killed off liver tumors in one-third of patients, study finds

  Thomas Marron

  27/01/22 → 29/01/22

  9 items of Media coverage

  Press/Media

• Immunotherapy before surgery may benefit patients with liver cancers

  Thomas Marron

  28/01/22

  1 item of Media coverage

  Press/Media

• Neoadjuvant cemiplimab promising for resectable liver cancer

  Thomas Marron

  27/01/22 → 28/01/22

  2 items of Media coverage

  Press/Media

• Immunotherapy before surgery in liver cancer patients can kill the tumour In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in

  Thomas Marron

  25/01/22

  1 item of Media coverage

  Press/Media

• Launching the Institute for Airway Sciences with Eric Genden, MD, MBA

  Charles Powell

  25/01/22

  2 items of Media coverage

  Press/Media

• Immunotherapy Before Liver Cancer Surgery Can Kill Tumor, and Likely Residual Cancer Cells.

  Thomas Marron & Miriam Merad

  20/01/22

  1 item of Media coverage

  Press/Media

• Immunotherapy Before Liver Cancer Surgery Can Kill Tumor, and Likely Residual Cancer Cells; Immunotherapy given before surgery caused liver cancer tumors to die off in one-third of the patients enrolled in a first-of-its-kind clinical trial, Mount Sinai r

  Thomas Marron & Miriam Merad

  19/01/22 → 20/01/22

  2 items of Media coverage

  Press/Media

• Immunotherapy Before Surgery Confirmed to Help Against Liver Cancer

  Thomas Marron

  20/01/22

  1 item of Media coverage

  Press/Media

• Immunotherapy before liver cancer surgery can kill tumour, and likely residual cancer cells

  Thomas Marron

  19/01/22

  1 item of Media coverage

  Press/Media

• Mount Sinai Launches Institute for Airway Sciences

  Marek Mlodzik & Charles Powell

  12/01/22 → 15/01/22

  4 items of Media coverage

  Press/Media

• Ten Medical and Scientific Breakthroughs of 2021 at Mount Sinai

  Samir Parekh, Thomas Fuchs, Thomas Marron, Cheryl Corcoran & Robert Hirten

  28/12/21 → 30/12/21

  2 items of Media coverage

  Press/Media

• Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

  Matthew Galsky,

  23/12/21

  1 item of Media coverage

  Press/Media

• Rusfertide Leads to Hematocrit Control in Patients With Polycythemia Vera

  Ronald Hoffman

  17/12/21

  1 item of Media coverage

  Press/Media

• Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

  Ronald Hoffman

  12/12/21 → 13/12/21

  80 items of Media coverage

  Press/Media

• Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting; A new Phase 2 study of rusfertide in PV patients with high hematocrit levels demonstrated rapid hematocrit control without the need for

  Ronald Hoffman

  12/12/21

  2 items of Media coverage

  Press/Media

• Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting'

  Ronald Hoffman

  12/12/21

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System: Potentially Serious Side Effect Seen in Patient after Immunotherapy

  Samir Parekh, Miriam Merad, Seunghee Kim-Schulze, Joshua Brody, Adeeb Rahman & Sundar Jagannath

  10/12/21 → 11/12/21

  8 items of Media coverage

  Press/Media

• CURE® Celebrates Eight Individuals’ Contributions at the 9th Annual MPN Heroes ProgramArticle

  Ronald Hoffman

  9/12/21

  1 item of Media coverage

  Press/Media

• Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

  Matthew Galsky,

  22/11/21

  1 item of Media coverage

  Press/Media

• Scientists identify new types of a blood cancer and potential targeted treatments

  David Melnekoff, Joshua Richter, Samir Parekh, Violetta V. Leshchenko, Ajai Chari & Sundar Jagannath

  17/11/21

  1 item of Media coverage

  Press/Media

• Antengene To Release Preliminary Results Of Selinexor For The Treatment Of Peripheral T-Cell Lymphoma And NK/T-Cell Lymphoma At The 2021 ASH Annual Meeting

  Sundar Jagannath

  9/11/21

  38 items of Media coverage

  Press/Media

• -Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  Sundar Jagannath

  5/11/21

  1 item of Media coverage

  Press/Media

• Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  Sundar Jagannath

  4/11/21

  16 items of Media coverage

  Press/Media

• CURE® Honors Oncologists, Patient Advocate in Lung Cancer Heroes® Award Program for on Impact Lung Cancer CommunityArticle

  Ramon Parsons,, Matthew Galsky,, Fred Hirsch, Fred Hirsch & Kenneth Rosenzweig

  29/10/21

  2 items of Media coverage

  Press/Media

• Clinical Trial: Pediatric GVHD Low Risk Steroid Taper Trial

  John Levine

  23/10/21

  2 items of Media coverage

  Press/Media